Latest Commercial Readiness News

Viridis Mining and Minerals has secured a prime site and finalized key contracts for its Rare Earth Research and Processing Centre in Brazil, positioning itself as a critical Western-aligned rare earth supplier amid tightening Chinese export controls.

Metallium Limited is set to commission its first Flash Joule Heating processing line in Texas by December 2025, expanding capacity fivefold and adding a second rare earth demonstration line. This move positions the company as a key player in non-Chinese critical metals refining amid tightening Chinese export controls.

Brazilian Critical Minerals Ltd has raised A$6 million through a well-supported placement to fast-track its flagship Ema Rare Earths Project in Brazil, aiming to move closer to commercial production.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Latrobe Magnesium Limited has successfully commenced production of Magnesium Oxide at its Hazelwood North Demonstration Plant, marking a significant operational milestone. The company is advancing towards steady-state output and exploring by-product commercialisation.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.